BACKGROUND:: The US Food and Drug Administration (FDA) approved pregabalin in
December 2004 for the treatment of neuropathic pain associated with diabetic peripheral …

OBJECTIVE To review pregabalin's pharmacology, pharmacokinetics, efficacy, and adverse
effects in the treatment of neuropathic pain, epilepsy, and anxiety. DATA SOURCES A …

Purpose. The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and
dosage and administration of pregabalin are reviewed. Summary. Pregabalin is the first drug …

In July 2004, pregabalin (Lyrica; Pfizer) was approved in Europe for the treatment of
peripheral neuropathic pain and as an adjunctive therapy for partial seizures in patients with …

Pregabalin is a new synthetic molecule and a structural derivative of the inhibitory
neurotransmitter γ-aminobutyric acid. It is an α 2-δ (α 2-δ) ligand that has analgesic …

Pregabalin is a recently licensed and marketed antiepileptic drug for use as adjunctive
treatment of partial epilepsy. It acts at presynaptic calcium channels, modulating …

Pregabalin (Lyrica, Pfizer) is a GABA analog with similar structure and actions to
gabapentin. It has antiepileptic, analgesic and anxiolytic activity. Pregabalin is indicated for …

Background: Pregabalin is an α2-δ ligand that has anxiolytic, analgesic, and anticonvulsant
properties. Objective: To establish the efficacy, safety, and tolerability of pregabalin …

Pfizer is developing pregabalin, a follow-up compound to its GABA agonist gabapentin, for
the potential treatment of several central nervous system (CNS) disorders including …

Abstract▴ Pregabalin, the pharmacologically active S-enantiomerof 3-aminomethyl-5-methyl-
hexanoic acid, has a similar pharmacological profile to that of its developmental …